Ligand id: 7386

Name: albiglutide

1. Baggio LL, Huang Q, Brown TJ, Drucker DJ. (2004)
A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.
Diabetes, 53 (9): 2492-500. [PMID:15331566]
2. Chuang VT, Kragh-Hansen U, Otagiri M. (2002)
Pharmaceutical strategies utilizing recombinant human serum albumin.
Pharm. Res., 19 (5): 569-77. [PMID:12069157]
3. Heard KR, Wu W, Li Y, Zhao P, Woznica I, Lai JH, Beinborn M, Sanford DG, Dimare MT, Chiluwal AK et al.. (2013)
A general method for making peptide therapeutics resistant to serine protease degradation: application to dipeptidyl peptidase IV substrates.
J. Med. Chem., 56 (21): 8339-51. [PMID:24044354]
4. Matthews JE, Stewart MW, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, Holland MC, Bush MA, Albiglutide Study Group. (2008)
Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.
J. Clin. Endocrinol. Metab., 93 (12): 4810-7. [PMID:18812476]
5. Tomkin GH. (2009)
Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes.
Curr. Opin. Mol. Ther., 11 (5): 579-88. [PMID:19806507]